

STATE-OF-THE-ART DETECTION AND ASSESSMENT OF NAFLD/NASH SUBJECTS

Using Non-Invasive Medical Imaging

The BioClinica Medical Imaging service utilizes our therapeutic expertise and best in-class image analysis and systems to provide comprehensive Non-Alcoholic Fatty Liver Disease (NAFLD) /Non-Alcoholic Steatohepatitis (NASH) trial support – from start to finish.

At BioClinica, we perform independent central review of non-invasive magnetic resonance imaging (MRI) techniques in clinical trials to expedite the assessment of disease severity and provide a more accurate monitoring of therapeutic response. Through our understanding of the complexities of NAFLD/NASH endpoints and broad therapeutic expertise, we help customize the imaging end points to the goals and objectives of your clinical trials.

Accelerate the detection and assessment of liver status through advanced medical imaging – and uncover evidence others might miss.

The BioClinica Advantage

Leverage our therapeutic expertise, regulatory leadership and global operations to inform and expedite your NAFLD/NASH clinical trials, from protocol design to regulatory submission and archiving of image data.

Our team is here to assist with:

- Development of imaging protocols and an imaging charter
- Robust site setup, qualification, and training
- Extensive quality review of incoming data
- Rapid eligibility analysis by global internal readers

Enhanced Capabilities for Sponsors

Enroll and retain subjects with timely image reads that are right the first time.

- Utilize collect-and-hold strategies to maximize your imaging investment
- Achieve accurate, consistent, reliable, and high-quality data through expert, independent, software-assisted review of liver images and quantitative analysis
- Stay on top of trial status with real-time access to eligibility and safety reports
- Transfer a wide range of image formats to external vendors and partners

MODALITY:

Magnetic Resonance Imaging — Proton Density Fat Fraction (MRI-PDFF) and Magnetic Resonance Elastography (MRE)

ENDPOINTS:

Individual liver Couinaud segment and overall fat fractions; Stiffness to correlate with fibrosis

MODALITY:

Abdominal MRI using T2W and T1W fast spin echo sequences

ENDPOINTS:

Subcutaneous and visceral adipose tissue (SAT/VAT) depot analysis

CLINICAL TRIAL EXPERIENCE

18+

liver studies

1800+

magnetic resonance imaging – proton density fat fraction (MRI-PDFF) analyses

225+

study sites

500+

MR elastography (MRE) analyses

600+

SAT/VAT segmentation

2-3

day turnaround for eligibility image reads